Hummingbird Diagnostics GmbH, a leader in the analysis of blood-based small RNA (sRNA) for the early detection and characterization of diseases, today announced the start of a clinical trial that examines the diagnostic performance of miLungDx, a blood-based sRNA panel for the detection of non-small cell lung cancer (NSCLC).

The primary endpoint of the prospective, longitudinal observational study (NCT05987189) is the detection of the absence or presence of lung cancer, according to the imaging and pathological follow-up data determined throughout the study period. The study conducted in the USA will include 2,000 patients, with patient registration expected to be completed 12 months after the start of the study.

"The start of patient registration for this clinical study is a significant milestone for the Hummingbird Diagnostics team and underlines our goal of improving health care by developing novel sRNA blood tests," explains Dr. Bruno Steinkraus, Chief Scientific Advisor at Hummingbird Diagnostics. "We are convinced that miLungDx offers the best performance reported so far from a blood test for early-stage lung cancer. We are looking forward to the further development of this RNA panel."

Hummingbird Diagnostics has published the best-in-class performance in the early detection of lung cancer in the Journal of Thoracic Oncology and presented it at ASCO 2023.